Integral Molecular reaches milestone in I-O target discovery collaboration with Daiichi Sankyo
Integral Molecular, the industry leader in discovering antibodies against multipass membrane proteins, today announced that it has successfully reached the first milestone in its collaboration with Daiichi Sankyo Co., Ltd. to discover new immuno-oncology (I-O) therapeutic targets. Integral Molecular utilized its Membrane Proteome Array (MPA) platform to find novel protein targets that can regulate the…
Details